Upfront Briefing
The FDA handed Celcuity its first launch asset, clearing Revtorpyk in PIK3CA wild-type breast cancer and flipping the story from binary approval risk to launch execution. AstraZeneca reached into China for the second time in a month, securing global rights to Dizal's oral lung-cancer pill Zegfrovy for $600M up front — up to $1.5B with milestones.
And at AAIC, Biogen and Ionis handed the tau hypothesis its first real cognitive win with diranersen, though the stock slid on a messy dose story. Three names, three ways to move a stock — with China BD&L (Dizal, Avere, Spero) once again doing the heavy lifting.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,543.59 |
0.4% |
9.6% |
| Nasdaq 100 |
29,586.29 |
1.1% |
16.1% |
| Russell 2000 |
2,964.76 |
0.4% |
17.7% |
| Healthcare (XLV) |
158.29 |
(1.9%) |
3.8% |
| Biotech (XBI) |
155.65 |
0.2% |
27.8% |
| Nasdaq Biotech (NBI) |
6,516.5 |
(0.5%) |
14.7% |
| Clinical Trials (BBC) |
51.57 |
0.5% |
37.1% |
|
- Biotech and pharma lagged a tech-led tape: a soft June CPI print pushed money into semis and megacap tech, leaving healthcare the weakest S&P 500 sector Tuesday, with XBI roughly flat while large-cap defensives took the hit.
- The broad tape firmed after June CPI landed at 3.5% versus the 3.8% consensus, cooling rate-hike fears — though a ~25% IBM plunge on an earnings warning and mixed big-bank prints (Goldman up, Citi and Wells down) kept the Dow pinned near flat.
- Market data: U.S. cash close Tuesday, 14 July 2026.
The Big 3
|
1
|
FDA approves Celcuity breast cancer drug Revtorpyk
|
- Revtorpyk, Celcuity's breast cancer drug, won FDA approval in combination with fulvestrant, giving the company its first commercial launch asset.
- Why it matters: The nod hands Celcuity (CELC) its first marketed product and turns a binary approval bet into a launch-execution story — shares jumped ~7% to close at $111.05. VIKTORIA-1 backs it: the triplet cut progression-or-death risk 76% (PFS 9.3 vs 2.0 months on fulvestrant), the doublet 67%. A Q3 sNDA in the PIK3CA-mutant cohort widens the pool, and Fierce reports Celcuity's CEO already fielding the obvious question — whether a de-risked, newly commercial breast-cancer asset belongs inside a larger oncology franchise. Watch uptake against entrenched CDK4/6 regimens and payer coverage on a targeted label.
- Source: Endpoints
- More: Fierce Pharma; FDA
|
|
2
|
AstraZeneca licenses Dizal's lung-cancer pill Zegfrovy for $600M up front
|
-
AstraZeneca secured exclusive worldwide rights to Zegfrovy (sunvozertinib), Dizal's oral EGFR exon 20 insertion NSCLC inhibitor already approved in the U.S. and China, for $600M up front, up to $900M in milestones and tiered royalties.
-
Why it matters: The prize is first-line: WU-KONG28 showed PFS of 10.3 vs 7.5 months against chemo, putting an oral pill directly against J&J's IV Rybrevant — today's only approved front-line option in exon20ins disease. AZ is buying revenue, not a project: Zegfrovy already sells in two major markets, with a first-line sNDA filed at the FDA and China's CDE under Breakthrough Therapy. It's AZ's second China license in a month after the Sino COPD pact, which keeps the COINS Act/BINSA overhang firmly in frame — every China-sourced BD&L now drags that regulatory tail into diligence.
-
Source:
Endpoints
-
More:
AstraZeneca;
Pharmaceutical Technology
|
|
3
|
Biogen's anti-tau oligo slows Alzheimer's decline — but only at the low dose
|
-
At AAIC, Biogen and Ionis reported Phase 2 Celia data for diranersen, an antisense oligonucleotide that blocks tau production; the 60 mg dose slowed cognitive decline across multiple scales at 18 months.
-
Why it matters: The first genuinely convincing cognitive signal for a tau-lowering drug — but a messy one. The 60 mg arm (n=60) slowed decline 26% on CDR-SB, 42% on ADAS-Cog and 50% on MMSE at 18 months, yet the strongest effect landing at the lowest dose is why the trial missed its dose-dependent primary, and BIIB/IONS shares slid on the ambiguity. Still, it validates tau as the next Alzheimer's target after amyloid, sidesteps the ARIA brain-bleeding that dogs Leqembi and Kisunla, and leaves room for combinations rather than replacement. Biogen is racing to Phase 3 without committing to a dose — with Voyager and Denali right behind.
-
Source:
Fierce Biotech
-
More:
Fierce Biotech
|
Everything Else that broke
- Kelun-Biotech said sac-TMT plus pembrolizumab beat chemotherapy in Phase III first-line PD-L1-negative non-squamous NSCLC. — PR
- ORIC started the global Phase III Himalayas-1 trial of rinzimetostat plus NUBEQA in mCRPC. — PR
- Biotech IPOs surged in H1 2026, with BioSpace saying issuance shattered records and doubled last year's total. — BioSpace
- CVS Caremark settled the FTC's insulin suit and must stop preferring higher-cost versions on standard formularies. — BioPharma Dive
- Boehringer Ingelheim reported H1 2026 net sales up 16.2% to EUR 15.8B, led by JARDIANCE. — PR
- BINSA, the House bill targeting China biotech deals, remains in play even as the effort sits in limbo. — Fierce Biotech
- Lynk completed Phase III enrollment for zemprocitinib in ankylosing spondylitis on July 9. — PR
- Castle won New York approval for AdvanceAD-Tx, its atopic dermatitis treatment-guidance test. — PR
- A Cayman judge ordered an Apple Tree partner to give up oversight of a venture fund. — BioPharma Dive
- Very high p-tau217 was linked to a 78% 10-year risk of cognitive impairment in older adults. — PR
- Spero Therapeutics pivoted into immunology and inflammation with a deal for an Innovent antibody worth up to $1.1B. — Fierce Biotech
- The FDA granted Priority Review to Roche's Gazyva/Gazyvaro (obinutuzumab) in primary membranous nephropathy, teeing up a potential first-in-disease approval on the back of MAJESTY's win over tacrolimus. — Roche
- Leica Biosystems (Danaher) struck a definitive agreement to acquire privately held StatLab Medical Products from Linden Capital and Audax; terms undisclosed. — PR
- Summit Therapeutics sold failed C. diff antibiotic ridinilazole to OpenAI- and Founders Fund-backed Biossil for $500K upfront plus up to $104.5M in milestones. — Fierce Biotech
- The ex-Akero team went public via a NextCure reverse merger (Nasdaq: AVRX), licensing Hansoh's weekly oral IL-23 pill AVR-001 for $120M upfront (up to $2.18B) and raising a $320M PIPE to fund a 2027 psoriasis Phase 2b. — Fierce Biotech
- The FDA confirmed its complete-response-letter release policy has resumed after an April pause, publishing 14 new CRLs on July 10 with more to follow and a proposed rule to formalize it. — Fierce Biotech
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
AstraZeneca licensed worldwide rights to Dizal's Zegfrovy (sunvozertinib) — $600M upfront, up to $900M milestones plus royalties. — Endpoints
- Leica Biosystems (Danaher) agreed to acquire StatLab Medical Products from Linden Capital and Audax; terms undisclosed. — PR
-
Avere licensed Hansoh's oral IL-23 asset AVR-001 (ex-China) — $120M upfront, up to $2.18B milestones plus royalties — concurrent with a NextCure reverse merger. — Fierce Biotech
- Insilico Medicine and Bora Pharmaceuticals formed an AI drug discovery and development alliance. — PR
- Spero Therapeutics pivoted into immunology and inflammation with an Innovent antibody deal worth up to $1.1B. — Fierce Biotech
VC / Private Financings
- Chai Discovery raised a $400M Series C at a $3.8B valuation, led by Index Ventures with Kleiner Perkins, Sequoia and Dimension — its third round in under a year. — Fierce Biotech
IPOs / Follow-Ons
- Avere Therapeutics priced a $320M private placement alongside its NextCure reverse merger and Nasdaq listing (AVRX). — Fierce Biotech
- Senhwa Biosciences secured an up-to-NT$500M standby equity purchase agreement with GEM. — PR
- Q32 Bio priced a $200M public offering of common stock and pre-funded warrants. — PR
|
